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Aspergillus fumigatus UDP-galactopyranose mutase (AfUGM) is a potential
drug target involved in the synthesis of the cell wall of this fungal pathogen.
AfUGM was recombinantly produced in Escherichia coli, puriﬁed and
crystallized by the sitting-drop method, producing orthorhombic crystals that
diffracted to a resolution of 3.25 A ˚ . The crystals contained four molecules per
asymmetric unit and belonged to space group P212121, with unit-cell parameters
a = 127.72, b = 134.30, c = 173.84 A ˚ . Incorporation of selenomethionine was
achieved, but the resulting crystals did not allow solution of the phase problem.
1. Introduction
Medical advances have led to an expanding and diverse immuno-
suppressed population that is susceptible to opportunistic pathogens,
including fungi. Consequently, infection in an immunocompromised
host presents a spectrum of clinical, diagnostic and therapeutic
challenges, often resulting in a considerable source of morbidity and
mortality. Of concern is an epidemiological shift towards invasive
fungal infections by Aspergillus species (Lass-Flo ¨rl, 2009). A. fumi-
gatus (Af) is responsible for 90% of invasive aspergillosis (IA), in
which primarily pulmonary infections can disseminate to any organ
(Denning, 1998). Approximately 24–40% of at-risk patients (for
example, those undergoing treatment for haematological malig-
nancies) develop signiﬁcant disease (Caira et al., 2010), with mortality
rates of up to 90% (Zmeili & Soubani, 2007), reﬂecting inherent
problems in the diagnosis and treatment of IA. Voriconazole is
currently regarded as a ﬁrst-line therapy (Herbrecht et al., 2002)
for invasive disease, but there are profound drug–drug interactions,
toxicity issues and initial reports of resistance (Howard et al., 2009;
Bueid et al., 2010). Overall, this situation represents considerable
medical risk, partly owing to a lack of novel antifungal drug targets in
the pipeline of the pharmaceutical industry.
The fungal cell wall is a dynamic, interlaced and only partially
deﬁned polysaccharide structure that is essential for survival
(Gastebois et al., 2009). Like glucan and chitin, galactomannan is a
major component of the cell wall in A. fumigatus, forming a linear
core of mannan branched with short  (1–5)-linked galactofuranose
(Galf) side chains. Galf formsthe outer edge of thecell wall and isthe
target of a serological diagnostic test for Aspergillus (Stynen et al.,
1992). The only source of Galf is by conversion from galactopyranose
(Galp) by the enzyme UDP-galactopyranose mutase (UGM; Trejo et
al., 1971; Nassau et al., 1996). UGM (EC 5.4.99.9) is a ﬂavo-containing
enzyme that catalyses the isomerization of the six-membered ring
(pyranose) form of galactose (Galp) to the ﬁve-membered ring form
(Galf). Deletion of the AfUGM gene resulted in marked defects on
solid media and a reduction in cell-wall thickness and growth rate,
and attenuated virulence has been demonstrated in an animal model
(Schmalhorst et al., 2008). These ﬁndings were contradicted by a
second report of an AfUGM knockout using a different strain
(Lamarre et al., 2009), leading to uncertainty as to the importance of
UGM, and further work is required to resolve this. Crucially, UGM is
absent in higher eukaryotes, making it a potential target for structure-
based drug design.The Galf biosynthetic pathway has been extensively studied in
prokaryotes (Richards & Lowary, 2009) and structural data have led
to insights into the mechanism of prokaryotic UGM (Sanders et al.,
2001; Beis et al., 2005; Gruber, Borrok et al., 2009; Gruber, Westler et
al., 2009; Partha et al., 2009, 2010). Although the prokaryotic and
eukaryotic UGMs show less than 20% sequence conservation
(Bakker et al., 2005; Beverley et al., 2005), the active site contains
conserved residues (Oppenheimer et al., 2010).
Our understanding of the structure and mechanism of AfUGM is
very limited as there are no available crystal structures of any
eukaryotic UGMs. To further characterize UGM as a potential drug
target, detailed structural information on AfUGM is required; this
communication describes the cloning, overexpression, puriﬁcation,
crystallization and preliminary X-ray diffraction data of AfUGM,
including a selenomethionine (SeMet) derivative.
2. Materials and methods
2.1. Cloning and transformation
The gene coding for AfUGM (GenBank accession No.
AJ871145.2) was obtained by PCR from a shuttle plasmid
(GenScript) containing an optimized sequence using the forward
primer 50-CCTGGGATCCATGACGCATCCGGACATCTC-30 and
the reverse primer 50-TCGAGCGGCCGCTTACTGCGCTTTGCT-
TTTGC-30.T h eBamHI and NotI restriction sites are shown in bold.
The PCR product was digested with BamHI and NotI and subcloned
into the pGEX6P1 plasmid, which encodes an N-terminal glutathione
transferase (GST) tag and a PreScission protease cleavage site
(Amersham Biosciences). Three residues (glycine, leucine and
proline) remained after proteolytic cleavage of the GST tag. All
plasmids were veriﬁed by sequencing (College of Life Sciences,
University of Dundee).
2.2. Expression and purification
The pGEX6P1-AfUGM plasmid was transformed into Escherichia
coli BL21 (DE3) pLysS strain and grown in Luria–Bertani (LB)
medium supplemented with 50 mgm l
 1 ampicillin. Cells were
cultured at 310 K and 120 rev min
 1 until an OD600 of 0.6 was
reached. Expression of the protein was induced by 0.25 mM isopropyl
 -d-1-thiogalactopyranoside (IPTG) at 291 K and 120 rev min
 1 with
an additional 48 h incubation. The cells were harvested by centrifu-
gation at 4000 rev min
 1 at 277 K for 30 min and the pellet was
resuspended in buffer consisting of 25 mM Tris, 150 mM NaCl pH 7.5.
After the addition of 0.1 mg ml
 1 DNAse and 1 mg ml
 1 lysozyme,
the cells were lysed using a high-pressure homogenizer (Emuliﬂex
C3, ATA Scientiﬁc) on ice. The ruptured cell debris was removed by
centrifugation at 18 000 rev min
 1 at 277 K for 1 h. The supernatant
was passed through Glutathione–Sepharose 4B beads (GE Health-
care) equilibrated with lysis buffer by gravity. The GST tag was
removed by overnight cleavage with PreScission protease at
10 rev min
 1 at 277 K. The released AfUGM protein was further
puriﬁed by size-exclusion chromatography (Superdex 75, GE
Healthcare). The protein was concentrated and analysed by SDS–
PAGE.
To obtain an SeMet-derivative AfUGM, the auxotrophic E. coli
B893 (DE3) pLysS strain (Calbiochem) was grown in Seleno-
Methionine Medium Base plus Nutrient Mix (Molecular Dimen-
sions). Following overnight culture in LB medium supplemented with
50 mgm l
 1 ampicillin, the supernatant was removed by centrifuga-
tion. The cell pellet was resuspended in SelenoMethionine Medium
containing 40 mg ml
 1 methionine (Molecular Dimensions) and
cultured (as above) for 4 h. Selenomethinone at 40 mg ml
 1 (Mole-
cular Dimensions) was added to the medium and after 30 min
expression was induced with 1 mM IPTG for 4 h. Incorporation of
SeMet was veriﬁed by mass spectrometry.
2.3. Crystallization and data collection
Commercial crystallization kits from Hampton Research and
Molecular Dimensions were used for sparse-matrix screening of
conditions and were followed by additive screens and further rounds
of optimization to produce diffracting crystals. Crystallization was
performed at 293 K using the sitting-drop vapour-diffusion method
[0.5 ml protein solution ( 15 mg ml
 1) mixed with 0.5 ml reservoir
solution and equilibrated against 70 ml reservoir solution]. Initially,
rhomboid crystals were observed in JCSG-plus screen (Molecular
Dimensions) condition 1.7 (0.1 M CHES pH 9.5, 20% PEG 8000)
after 24–48 h. Despite optimizing this condition, the crystals failed to
diffract. Further screening trials involved varying the PEG concen-
tration/molecular weight, buffer and introducing a salt. The resulting
condition (0.1 M HEPES pH 7.5, 20% PEG 3350, 0.4 M ammonium
sulfate, 4% formamide) produced two crystal forms: hexagonal rods
(which failed to diffract) and plates.
AfUGM was cocrystallized with various substrate/inhibitor/
reducing ligands, which were incubated with the protein for 10 min on
ice (10 mM UDP-Galp,1 0m M UDP, 5 mM UDP-glucose, 5–20 mM
sodium dithionite). Ultimately, a plate-shaped AfUGM crystal that
was cocrystallized with 5 mM fresh sodium dithionite and soaked
in 10 mg ml
 1 gold(I) potassium cyanide (Hampton Research) for
60 min and an SeMet-derivative crystal were employed for data
collection. Each crystal was mounted on a CryoLoop (Hampton
Research) and immersed into cryoprotectant (35% PEG 3350) for
several seconds before being ﬂash-cooled in liquid nitrogen. All data
collections were performed at 100 K under a stream of nitrogen gas.
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Figure 1
Coomassie Blue-stained 10% SDS–PAGE showing recombinant AfUGM puriﬁed
by size-exclusion chromatography. Lane M, molecular-weight markers (kDa). Lane
A, AfUGM.A data set was collected from a gold-soaked crystal to a resolution
of 3.25 A ˚ on beamline I04 at Diamond Light Source using a Q315
detector. A total of 82 images were collected with an exposure of 1.5 s
and 1.1  oscillation at a crystal-to-detector distance of 421.6 mm. For
SeMet-derivative AfUGM, beamline I24 (Diamond Light Source)
was tuned to theabsorption peak(12 666 eV)obtained from an X-ray
ﬂuorescence scan around the selenium edge. A data set consisting of
480 images with an exposure of 0.25 s and 0.5  oscillation at a crystal-
to-detector distance of 619.4 mm was collected to a resolution of
4.0 A ˚ . All diffraction data were integrated and scaled using
MOSFLM (Leslie & Powell, 2007) and SCALA (Evans, 2006).
3. Results and discussion
Recombinant GST-tagged native and SeMet-labelled AfUGM were
successfully produced in E. coli. After proteolytic removal of theGST
tag, the proteins were puriﬁed to homogeneity by size-exclusion
chromatography, eluting as a single peak; fractions that contained
UGM were indicated by the characteristic yellow colour of this
ﬂavonoid-containing protein. Analysis by SDS–PAGE (Fig. 1)
conﬁrmed the presence of pure protein corresponding to the
theoretical molecular mass of 57.2 kDa. Each litre of cell culture
yielded approximately 4 mg pure AfUGM.
Rhomboid crystals were observed within 2 d after initial sparse-
matrix screening, but failed to diffract. Following further optimiza-
tion, plate-shaped crystals (Fig. 2) were obtained by the sitting-drop
method with a mother liquor consisting of 0.1 M HEPES pH 7.5, 20%
PEG 3350, 0.4 M ammonium sulfate, 4% formamide. These were
used for data collection using synchrotron radiation (Diamond Light
Source). The best diffracting crystal, which diffracted to a resolution
of 3.25 A ˚ (Fig. 3), was soaked in gold potassium cyanide before data
collection, but no anomalous signal corresponding to heavy-atom
binding was observed; consequently, this constituted a native data set.
AfUGM consists of 510 amino acids, of which 15 are methionine
residues. To solve the phase problem, a data set collected from a
SeMet-labelled AfUGM crystal that diffracted to 4.0 A ˚ resolution on
beamline I24 at Diamond Light Source was processed. The data-
collection and processing statistics are summarized in Table 1. Both
crystals belonged to the orthorhombic space group P212121, with unit-
cell parameters a = 127.72, b = 134.30, c = 173.84 A ˚ for the native
crystal and a = 127.15, b = 133.16, c = 172.40 A ˚ for the SeMet deri-
vative. The volume of the asymmetric unit is compatible with four
molecules, as indicated by the Matthews coefﬁcient of 3.26 A ˚ 3 Da
 1
and the solvent content of 62% (Matthews, 1968). In contrast to
bacterial UGMs, which are dimers, AfUGM has been suggested to
exist as a tetramer (Oppenheimer et al., 2010). Inspection of a self-
rotation function did not reveal peaks that were compatible with
fourfold rotational symmetry.
No signiﬁcant anomalous signal was detected and attempts to
locate selenium sites using a range of computer programs failed.
Although the sequence homology between bacterial and eukaryotic
UGM is low, conserved regions are predicted in the FAD-binding
domain and active site (Oppenheimer et al., 2010). To further assist
with structure determination, molecular replacement was attempted
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Figure 2
Typical plate-shaped crystal of AfUGM with an approximate maximum dimension
of 10 mm belonging to the orthorhombic space group P212121. One of the plates was
separated from the cluster before data collection.
Figure 3
Representative X-ray diffraction image of native AfUGM. The crystal diffracted to
3.25 A ˚ resolution on beamline I04 at Diamond Light Source using a Q315 detector
at a wavelength of 0.96860 A ˚ . The exposure time was 1.5 s with 1.1   oscillation at a
crystal-to-detector distance of 421.6 mm.
Table 1
Data-collection statistics for native and SeMet AfUGM crystals.
Values in parentheses are for the highest resolution shell. The statistics were as output
from SCALA (Evans, 2006).
Native SeMet
Beamline Diamond I04 Diamond I24
Temperature (K) 100 100
Wavelength (A ˚ ) 0.96860 0.97889
Space group P212121 P212121
Unit-cell parameters (A ˚ ,  ) a = 127.72, b = 134.30,
c = 173.84,
  =   =   =9 0
a = 127.15, b = 133.46,
c = 172.40,
  =   =   =9 0
Resolution (A ˚ ) 39.80–3.25 (3.43–3.25) 39.53–4.00 (4.22–4.00)
Observed reﬂections 168113 191408
Unique reﬂections 46060 24889
Multiplicity 3.6 (3.7) 7.7 (7.6)
Completeness (%) 97.1 (98.9) 98.3 (98.1)
Rmerge† (%) 0.161 (0.478) 0.159 (0.384)
hI/ (I)i 5.7 (2.4) 10.6 (5.0)
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) and hI(hkl)i are the
observed intensity and the average intensity of multiple observations of symmetry-
equivalent reﬂections, respectively.using bacterial UGM structures from the Protein Data Bank (for
example, Deinococcus radiodurans UGM; PDB entry 3he3), but this
was also unsuccessful. In conclusion, this communication describes
the production of recombinant crystallization-grade AfUGM, its
crystallization and preliminary X-ray diffraction data.
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